10 Top Insider Stock Buys And Sells In January

5. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of insiders selling: 10

Market Cap: $11.49 billion

Neurocrine is a biopharmaceutical company focused on the discovery and development of medicine for the treatment of neurological, endocrine, and psychiatric disorders. Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH).

In addition to Ingrezza, Neurocrine’s diverse portfolio contains other FDA-approved treatments, such as those for classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.

In January, 10 insiders, among which are the company’s CEO, CFO, and CCO sold a total of around $33 million worth of Neurocrine shares at an average price of $151.04. Out of the total amount, the company’s CEO, Kyle Gano, sold 66,541 shares, worth $9.43 million reducing his holding to 136,778 at the time.

The stock is now trading at $115.11 per share, having declined 15.78% year-to-date.

For the full year ended December 31, 2024, Neurocrine disclosed Ingrezza net sales of $2.36 billion, compared to $1.89 billion in 2023.

On January 28, the company launched a Phase 3 registrational study to assess the efficacy, safety, and tolerability of osavampator, an investigational drug being developed as an additional treatment to antidepressants for major depressive disorder (MDD).

Neurocrine is also one of the 12 Best Low Risk High Growth Stocks to Invest In.